BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE (NASDAQ: BNTX) is a global biotechnology company headquartered in Mainz, Germany, that develops and manufactures active immunotherapies for a range of diseases. Using its proprietary messenger RNA (mRNA) technology platform, BioNTech designs novel treatments that harness the body’s immune system to target cancer, infectious diseases and other serious medical conditions. The company’s research and development efforts span oncology, rare diseases and vaccines, with an emphasis on personalized approaches.

Central to BioNTech’s business is its mRNA-based pipeline, which includes individualized cancer vaccine candidates tailored to a patient’s tumor profile, as well as off-the-shelf modalities for solid tumors and hematological malignancies. Beyond oncology, BioNTech has advanced infectious disease vaccines, most notably its collaboration with Pfizer to co-develop a COVID-19 vaccine. The success of this partnership has reinforced the company’s platform validity and expanded its manufacturing footprint in Europe and North America.

Founded in 2008 by husband-and-wife team Dr. Ugur Sahin and Dr. Özlem Türeci, BioNTech has grown from a small startup into a publicly traded entity following its initial public offering on the Nasdaq in 2019. The company’s leadership team combines academic expertise and industry experience, with Dr. Sahin serving as Chief Executive Officer. BioNTech maintains research sites in Germany and the United States and collaborates with global academic institutions, biopharmaceutical partners and public health organizations to accelerate the development and distribution of its products.

BioNTech’s operations extend across Europe, North America and select international markets, supported by strategic partnerships that facilitate clinical trials, regulatory approvals and large-scale manufacturing. The company continues to advance its mRNA platform into new therapeutic areas, pursuing collaborations and in-licensing opportunities to broaden its pipeline and address emerging medical needs worldwide.

Key Stats

• Today's Range: $104.26 to $106.52
• 50-Day Range: $96.22 to $113.52
• 52-Week Range: $81.20 to $129.27
• Volume: 535,700 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $25.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $134.56
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 54% of companies evaluated by MarketBeat, and ranked 525th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 11 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

BioNTech has a consensus price target of $134.56, representing about 27.6% upside from its current price of $105.49.

Amount of Analyst Coverage

BioNTech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BioNTech are expected to decrease in the coming year, from ($3.88) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioNTech is -65.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioNTech is -65.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioNTech has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.70% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in BioNTech has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.70% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in BioNTech has recently increased by 5.98%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.10

News Sentiment

BioNTech has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BioNTech this week, compared to 12 articles on an average week.

Search Interest

47 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 161% compared to the previous 30 days.

MarketBeat Follows

5 people have added BioNTech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.52% of the stock of BioNTech is held by institutions.

BNTX Stock Analysis - Frequently Asked Questions

How have BNTX shares performed this year?

BioNTech's stock was trading at $113.95 at the beginning of the year. Since then, BNTX shares have decreased by 7.4% and is now trading at $105.49.

How were BioNTech's earnings last quarter?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) released its quarterly earnings data on Monday, August, 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by $0.19. The company's quarterly revenue was up 102.6% on a year-over-year basis.
Read the conference call transcript.

Does BioNTech have any subsidiaries?

BioNTech subsidiaries include these companies: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more.

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's top institutional investors include GAMMA Investing LLC.

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTX
• CIK: 1776985
• Web: www.biontech.de
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 6,772
• Year Founded: 2008

Price Target and Rating

• Average Price Target for BioNTech: $134.56
• High Price Target: $171.44
• Low Price Target: $110.00
• Potential Upside/Downside: +27.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$719.92 million
• Net Margins: -12.20%
• Pretax Margin: -13.81%
• Return on Equity: -1.84%
• Return on Assets: -1.59%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.61
• Quick Ratio: 8.48

Sales & Book Value

• Annual Sales: $2.98 billion
• Price / Sales: 8.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $87.61 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 240,400,000
• Free Float: 194,242,000
• Market Cap: $25.36 billion
• Optionable: Optionable
• Beta: 1.45